secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001171843-25-001388
Event type: m_and_a
Sentiment:  positive
Materiality: 0.55
Item codes: 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika completes sale of Parcus Medical for $4.5M cash, sharpens focus on OA pain management
--------------------------------------------------------------------------------

- Sale closed March 7, 2025 to Medacta Group SA (Medacta Americas Manufacturing).
- Cash consideration of $4.5M at closing, subject to customary post-closing adjustments.
- Divestiture part of previously announced strategic review; company to focus on hyaluronic acid and regenerative solutions.
- Parcus Medical was a wholly owned subsidiary; Anika received total cash consideration at closing.
- Goodwin Procter served as legal counsel; Piper Sandler as exclusive financial advisor to Anika.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184325001388/0001171843-25-001388-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184325001388/f8k_031025.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001388

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer